Incidence of cognitively defined late-onset Alzheimer's dementia subgroups from a prospective cohort study

Alzheimer's and Dementia

Volumn 13, Issue 12, 2017, Pages 1307-1316

  Crane, Paul K ^a   Trittschuh, Emily ^b,c   Mukherjee, Shubhabrata ^a   Saykin, Andrew J ^d   Sanders, R Elizabeth ^a   Larson, Eric B ^e   McCurry, Susan M ^a   McCormick, Wayne ^a   Bowen, James D ^f   Grabowski, Thomas ^a,c   Moore, Mackenzie ^a   Bauman, Julianna ^a   Gross, Alden L ^g   Keene, C Dirk ^a   Bird, Thomas D ^a,b   Gibbons, Laura E ^a   Mez, Jesse ^h  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e KAISER PERMANENTE   (United States)

^f SWEDISH MEDICAL CENTER   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cognition; Endophenotypes; Genetics; Heterogeneity; Neuropathology; Subgroups

Indexed keywords

APOLIPOPROTEIN E4; APOLIPOPROTEIN E;

AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; COHORT ANALYSIS; DEMENTIA; DEPTH PERCEPTION; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; HUMAN; INCIDENCE; LANGUAGE ABILITY; LATE ONSET DISORDER; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; NEUROPATHOLOGY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; COGNITIVE DEFECT; COMPLICATION; GENETICS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PHYSIOLOGY; VERY ELDERLY; VISION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEINS E; COGNITION DISORDERS; COHORT STUDIES; EXECUTIVE FUNCTION; FEMALE; HUMANS; INCIDENCE; MALE; MEMORY DISORDERS; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; VISUAL PERCEPTION;

EID: 85022214893     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2017.04.011     Document Type: Article

References (28)

1. Gotovac, K., Hajnsek, S., Pasic, M.B., Pivac, N., Borovecki, F., Personalized medicine in neurodegenerative diseases: how far away?. Mol Diagn Ther 18 (2014), 17–24.
2. Kosik, K.S., Personalized medicine for effective Alzheimer disease treatment. JAMA Neurol 72 (2015), 497–498.
3. Cholerton, B., Larson, E.B., Quinn, J.F., Zabetian, C.P., Mata, I.F., Keene, C.D., et al. Precision medicine: clarity for the complexity of dementia. Am J Pathol 186 (2016), 500–506.
4. Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
5. Lezak, M.D., Neuropsychological Assessment. 3 ed., 1995, Oxford University Press, NY.
6. von Elm, E., Altman, D.G., Egger, M., Pocock, S.J., Gotzsche, P.C., Vandenbroucke, J.P., The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147 (2007), 573–577.
7. Spreen, O., Strauss, E., Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 1991, Oxford UP, NY.
8. Morris, J.C., Heyman, A., Mohs, R.C., Hughes, J.P., van Belle, G., Fillenbaum, G., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39 (1989), 1159–1165.
9. Mattis, S., Dementia Rating Scale. 1988, Psychological Assessment Resources, Odessa, FL.
10. Wechsler, D., WMS-R: Wechsler Memory Scale - Revised Manual. 1987, Psychological Corporation/HBJ, NY.
11. Reitan, R.M., Wolfson, D., The Halstead-Reitan Neuropsychological Test Battery. 1985, Neuropsychology Press, Tucson.
12. American Psychiatric Association. Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed., 1994, American Psychiatric Association, Washington, DC.
13. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
14. Crane, P.K., Gibbons, L.E., McCurry, S.M., McCormick, W., Bowen, J.D., Sonnen, J., et al. Importance of home study visit capacity in dementia studies. Alzheimers Dement 12 (2016), 419–426.
15. Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., et al. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). Brain Imaging Behav 6 (2012), 502–516.
16. Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., et al. A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment. Brain Imaging Behav 6 (2012), 517–527.
17. Mukherjee, S., Trittschuh, E., Gibbons, L.E., Mackin, R.S., Saykin, A., Crane, P.K., Dysexecutive and amnesic AD subtypes defined by single indicator and modern psychometric approaches: relationships with SNPs in ADNI. Brain Imaging Behav 6 (2012), 649–660.
18. van der Sluis, S., Verhage, M., Posthuma, D., Dolan, C.V., Phenotypic complexity, measurement bias, and poor phenotypic resolution contribute to the missing heritability problem in genetic association studies. PLoS One, 5, 2010, e13929.
19. Muthen, L.K., Muthen, B.O., Mplus User's Guide. 7th ed., 1998-2012, Muthen & Muthen, LA.
20. Ivnik, R.J., Malec, J.F., Smith, G.E., Tangalos, E.G., Petersen, R.C., Kokmen, E., et al. Mayo's older americans normative studies: WMS-R norms for ages 56 to 94. Clin Neuropsychol 6 (1992), 49–82.
21. Beeri, M.S., Schmeidler, J., Sano, M., Wang, J., Lally, R., Grossman, H., Silverman, J.M., Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old. Neurology 67 (2006), 1006–1010.
22. Sonnen, J.A., Larson, E.B., Walker, R.L., Haneuse, S., Crane, P.K., Gray, S.L., et al. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Neurology 75 (2010), 1203–1210.
23. Sonnen, J.A., Larson, E.B., Crane, P.K., Haneuse, S., Li, G., Schellenberg, G.D., et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol 62 (2007), 406–413.
24. Braak, H., Braak, E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82 (1991), 239–259.
25. Mirra, S.S., Heyman, A., McKeel, D., Sumi, S.M., Crain, B.J., Brownlee, L.M., et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991), 479–486.
26. Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Buros, J., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43 (2011), 436–441.
27. Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet 45 (2013), 1452–1458.
28. Schneider, J.A., Arvanitakis, Z., Bang, W., Bennett, D.A., Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69 (2007), 2197–2204.